154 related articles for article (PubMed ID: 9119158)
1. Future development of harmonized guidelines.
Hayakawa T
Dev Biol Stand; 1996; 88():331-2. PubMed ID: 9119158
[No Abstract] [Full Text] [Related]
2. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
Lubiniecki AS; McAllister PR; Smith TM; Shadle PJ
Dev Biol Stand; 1996; 88():309-15. PubMed ID: 9119154
[No Abstract] [Full Text] [Related]
3. Contamination of genetically engineered Chinese hamster ovary cells.
Burstyn DG
Dev Biol Stand; 1996; 88():199-203. PubMed ID: 9119137
[TBL] [Abstract][Full Text] [Related]
4. Issues related to harmonization of testing requirements for viral safety.
Hayakawa T
Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
[TBL] [Abstract][Full Text] [Related]
5. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
6. Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal--a strategy.
Wright G; Colman A; Cottom D; Williams M
Dev Biol Stand; 1996; 88():269-76. PubMed ID: 9119150
[No Abstract] [Full Text] [Related]
7. WHO Expert Committee on Biological Standardization.
World Health Organ Tech Rep Ser; 1994; 840():1-218. PubMed ID: 8203143
[No Abstract] [Full Text] [Related]
8. Experience with viral contamination in cell culture.
Garnick RL
Dev Biol Stand; 1996; 88():49-56. PubMed ID: 9119162
[TBL] [Abstract][Full Text] [Related]
9. Viral safety of biological products and the concept of validation.
Horaud F
Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
[No Abstract] [Full Text] [Related]
10. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
Adamson SR
Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
[TBL] [Abstract][Full Text] [Related]
11. Adventitious agents from animal-derived raw materials and production systems.
Hellman KB; Honstead JP; Vincent CK
Dev Biol Stand; 1996; 88():231-4. PubMed ID: 9119142
[No Abstract] [Full Text] [Related]
12. Validation of virus removal in large scale purification processes.
Fritsch E
Dev Biol Stand; 1992; 76():239-48. PubMed ID: 1478342
[No Abstract] [Full Text] [Related]
13. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
[No Abstract] [Full Text] [Related]
14. Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical.
McAllister PR; Shadle PJ; Smith TM; Scott RG; Lubiniecki AS
Dev Biol Stand; 1996; 88():111-21. PubMed ID: 9119122
[No Abstract] [Full Text] [Related]
15. The EEC and the regulation of blood derivatives.
Horaud F
Dev Biol Stand; 1993; 81():273-6. PubMed ID: 8174814
[No Abstract] [Full Text] [Related]
16. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
Wisher M
Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
[TBL] [Abstract][Full Text] [Related]
17. The regulation of medicinal products derived from human blood or plasma in the European Community.
Brunko P
Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813
[No Abstract] [Full Text] [Related]
18. Future directions for ensuring viral safety of biopharmaceuticals.
Trent DW
Dev Biol Stand; 1996; 88():333-5. PubMed ID: 9119159
[No Abstract] [Full Text] [Related]
19. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
[No Abstract] [Full Text] [Related]
20. Relationship between nature and source of risk and process validation.
Berthold W; Werz W; Walter JK
Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
[No Abstract] [Full Text] [Related]
[Next] [New Search]
